
⁽¹²⁾ UK Patent Application ⁽¹⁹⁾ GB ⁽¹¹⁾ 2 134 516 A

(21) Application No. 8402735

(22) Date of filing
2 Feb 1984

(30) Priority data

(31) 8302968
8330479

(32) 3 Feb 1983
15 Nov 1983

(33) United Kingdom (GB)

(43) Application published
15 Aug 1984

(51) INT CL³ C07C 97/10
A61K 31/13

(52) Domestic classification
C2C 220 227 22Y 29X
29Y 313 31Y 322 32Y
338 351 355 35Y 620
625 650 665 802 80Y
AA LL

(56) Documents cited
None

(58) Field of search
C2C

(71) Applicant
The Wellcome
Foundation Limited
(United Kingdom)
183-193 Euston Road
London NW1 2BP

(72) Inventors
John Evelyn Warner
Billinghurst
David Arthur Yeowell
Jeffrey Douglas
Scharver

(74) Agent and/or Address for
Service
L D Jenkins
Langley Court
Beckenham
Kent BR3 3BS

(54) **Biologically active ketone derivative, preparation and use**

(57) 2-*tert*-Butylamino-3'-chloropropiophenone maleate, its preparation, pharmaceutical compositions containing it and their preparation, and its use in therapy, for example the treatment of depression in man.

GB 2 134 516 A

SPECIFICATION

Biologically active ketone derivative, preparation and use

- 5 The present invention relates to a novel salt of 2-*tert*-butylamino-3'-chloropropiophenone. 5
2-*tert*-Butylamino-3'-chloropropiophenone and the corresponding 3'-fluoro analogue are described in our British Patent Specification No. 1,340,032 which also broadly discloses the pharmaceutically acceptable salts of these bases, the salts of the following acids being specifically mentioned in the Specification, namely hydrochloric, sulphuric, phosphoric and
10 toluenesulphonic acids. As indicated in the Specification, the above described compounds 10
possess valuable anti-depressant properties when tested by standard techniques used in the art for determining anit-depressant activity, for example the tetrabenazine induced sedation test in rodents. It has been found that the compounds require much larger doses for stimulant action than for anti-depressant action. The compounds are also not inhibitors of monoamine oxidase
15 nor do they have a pressor effect. Of the two free bases and their salts mentioned above, the 15
chloro analogue and its pharmaceutically acceptable salts have been found to have particularly advantageous antidepressant activity.
- As mentioned in the Specification, 2-*tert*-butylamino-3'-chloropropiophenone and its 3'-fluoro analogue are moderately weak bases (pK_a about 8.5-9) and are desirably stored and administered as pharmaceutically acceptable salts, mineral acid salts and particularly the hydrochloride
20 salt being mentioned for this purpose in the Specification. 20
- However, it has now been found that problems arise in the selection of suitable salts for use as therapeutic agents because of poor stability when prepared and stored in bulk and/or when used to make pharmaceutical formulations. Thus, for example, from experiments which we have
25 carried out, we have found that the following salts of 2-*tert*-butylamino-3'-chloropropiophenone 25
are unstable upon storage, namely the salts of formic, fumaric, citric, phthalic and trifluoromethanesulphonic acids, as well as the phosphate monohydrate, hemisulphate sesquihydrate, methanesulphonate sesquihydrate, p-toluenesulphonate monohydrate and naphthalenesulphonate monohydrate salts. The propiophenone moiety breaks down into hydroxyketones, a diketone and
30 meta-chlorobenzoic acid. It is of course an important desideratum for a pharmaceutical product 30
that should have a reasonably good bulk stability in order to avoid or reduce wastage resulting from decomposition of the active moiety during the period between its synthesis and its use in formulating the final dosage form.
- A further problem is that the above-mentioned salts of the base and also the hydrochloride
35 have limited stability when formulated with conventional pharmaceutical carriers or excipients 35
into solid compositions. It will be appreciated that, in order for the salts to be used in medical therapy, it is necessary to formulate them into pharmaceutical compositions suitable for administration to the patient. The formulation of such compositions entails the admixture or contacting of the salts with various pharmaceutical carriers or excipients. Examples of solid
40 pharmaceutical compositions which are mentioned in British Specification 1,340,032 are 40
tablets, cachets, capsules and suppositories. Of these various types of composition, tablets and capsules are particularly preferred forms as it is generally desired to administer the active compound by the oral route. However, from experiments which we have carried out, we have found that the hydrochloride salt of 2-*tert*-butylamino-3'-chloropropiophenone has limited
45 stability in the presence of conventional tableting excipients, particularly magnesium stearate 45
and stearic acid which are commonly used as lubricants in tablet formulations. The formulation of the salts of the free base in capsules also presents problems because gelatin, which is commonly used to make the capsule shell, is hydrophilic and therefore creates a humid environment within the capsule, which has a deleterious effect on the 2-*tert*-butylamino-
50 3'-chloropropiophenone salt present in the capsule. It will therefore be appreciated that 50
considerable difficulty arose in finding a salt of 2-*tert*-butylamino-3'-chloropropiophenone which has sufficient stability when formulated in pharmaceutical compositions.
- We have now discovered that the maleate salt of 2-*tert*-butylamino-3'-chloropropiophenone has advantageous stability characteristics in association with conventional pharmaceutical
55 carriers and excipients, particularly carriers or excipients which are commonly employed in the 55
formulation of solid compositions such as tablets and capsules. A further advantage of the maleate salt is that it is much less corrosive than, for example, the hydrochloride salt which tends to corrode apparatus used in its preparation and formulation. A particular problem with the hydrochloride is that it tends to corrode tablet press die tables causing considerable
60 economic disadvantage. 60
- According to one feature of the present invention therefore we provide 2-*tert*-butylamino-3'-chloropropiophenone maleate.
- The use of the maleate salt of 2-*tert*-butylamino-3'-chloropropiophenone enables one to present the base in a substantially stable form which can be relatively easily prepared, then
65 stored in bulk for reasonable periods of time and/or which can be formulated in pharmaceutical 65

compositions particularly in solid compositions such as tablets and capsules, thereby avoiding the stability problems which, as discussed above, are associated with other salts. The maleate salt has been found to have good antidepressant activity when tested in the tetrabenazine-induced sedation test in rodents.

5 According to a further feature of the present invention we provide 2-*tert*-butylamino-3'-chloropropiophenone maleate for use in the therapeutic treatment of a mammal, for example, for use in the treatment of depression in mammals, including man. 5

The present invention also provides a method of treating depression in a mammal, including a human being, which comprises administering to said mammal an effective dose of 2-*tert*-butylamino-3'-chloropropiophenone maleate, for example in a form of a pharmaceutical composition as hereinafter described. 10

The present invention further provides a method of treating one or more of the following conditions in a mammal, including a human being, which comprises administering to said mammal a dose effective to treat said condition of 2-*tert*-butylamino-3'-chloropropiophenone maleate, for example, in a form of a pharmaceutical composition as hereinafter described: 1) minimal brain dysfunction; 2) tardive dyskinesia; 3) mania; 4) hypercholesterolemia; 5) hyperprolactinemia and other conditions wherein reduced prolactin secretion is desirable, such as prolactin sensitive mammary cancer, galactorrhea, etc.; 6) mental functional impairment caused by alcohol consumption; and 7) functional impairment and drowsiness caused by the use of benzodiazepines. 15 20

According to a further feature of the present invention we provide pharmaceutical compositions comprising, as active ingredient, 2-*tert*-butylamino-3'-chloropropiophenone maleate in association with at least one pharmaceutical carrier or excipient. Conveniently the said active ingredient comprises 5 to 95% by weight of the composition.

25 The above-described compositions according to the present invention are preferably presented in solid unit dosage forms for administration by the oral or rectal route, e.g. in the form of tablets, cachets, capsules or suppositories. They may also be presented in solution or suspension for oral administration or in solution for parenteral administration. 25

It is particularly preferred to present the maleate salt according to the present invention in an oral dosage unit preparation (e.g. as a cachet, tablet or capsule) containing one or more pharmaceutically acceptable carriers which may take the form of solid fillers or diluents such as lactose, starch such as corn, potato or rice starch, microcrystalline cellulose, as well as other excipients conventionally known in the pharmaceutical art for this purpose including binders, thickeners, lubricants, disintegrants, surfactants, buffers, sweetening and other flavouring agents, coloring agents, coatings and preservatives. As indicated above, a particularly preferred type of pharmaceutical composition for the administration of the maleate salt is the tablet comprising, in addition to the active ingredient, one or more of the above-mentioned pharmaceutical carriers or excipients suitable for tablet formulations, for example, inert diluents such as lactose and corn starch, and/or lubricants such as talc, hydrogenated vegetable oil, stearic acid, lubritab and magnesium stearate. Another preferred type of pharmaceutical composition is the capsule wherein the active ingredient optionally in admixture with one or more appropriate pharmaceutical carriers or excipients, e.g., selected from those described above, is presented in a capsule shell, for example, of gelatin. The gelatin capsule is preferably opaque and may be colored, generally being hard rather than soft gelatin. 30 35 40

45 The formulation of the active ingredient as suppositories for rectal administration may be effected using conventional pharmaceutically acceptable carriers for this purpose such as cocoa butter. 45

For the oral or rectal route of administration, the preferred dosage of the active ingredient (calculated as the base) is about 0.25 mg/kg to 5 mg/kg of mammal body weight while the most preferred dosage (calculated as the base) is about 0.75 mg/kg to 3.5 mg/kg of mammal body weight. The active ingredient is preferably administered 3 times daily although the number of daily administrations of the medication may vary according to the subject (mammal) being treated, the nature of the formulation and the exercise of the physician's discretion. 50

For the treatment of humans, the preferred unit dosage of the active ingredient (calculated as the base) for oral administration, or administration as a suppository, is about 15 to 500 mg with the more preferred unit dosage being about 35 to 250 mg, and the most preferred unit dosage being amount 40 to 150 mg. 55

The compositions of the present invention may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier or excipient. In general the compositions are prepared by uniformly and intimately admixing the ingredients. This may be achieved by simple admixture but preferably involves granulation, dry or wet, in the latter instance with readily available liquids such as water or alcohol. The granules with or without compaction may then be compressed or molded into tablets or suppositories, or filled into capsules or cachets. Suppositories may also be made by melting the required base, e.g. the cocoa butter, mixing in the active ingredient, and molding 60 65

the mixture or allowing it to solidify, powdering or granulating this and then compressing the powder or granules into the suppository.

Other formulations suitable for oral administration include powders and granules; a bolus, electuary or paste; a solution or a suspension in an aqueous liquid or a non-aqueous liquid; and an oil-in-water or water-in-oil liquid emulsion.

The active ingredient may also be administered by the parenteral (including subcutaneous, intradermal, intramuscular and intravenous) route.

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

When administered by the parenteral route the required dosage of the active ingredient (calculated as the base) will generally be one-half of that indicated *supra* as appropriate for oral administration.

Preferred unit dosage preparations are those containing a unit dosage, as hereinabove recited, or an appropriate fraction thereof, of the active ingredient.

The compositions of the present invention as above described may optionally contain other therapeutic agents to complement and/or supplement the activity of the maleate salt.

2-*tert*-Butylamino-3'-chloropropiophenone maleate may be prepared in conventional manner, for example by analogous procedures to those described in British Patent Specification, 1,340,032. In principle, the two preferred methods of preparing the maleate are:-

(a) metathesis in solution or suspension of another salt of the base with maleic acid or a functional equivalent thereof; or

(b) treatment of the free base in solution or suspension with maleic acid or a functional equivalent thereof.

With regard to process (a), this may be conveniently effected by reacting the other salt of the base with maleic acid on a solvent medium, preferably in an aqueous medium. The reaction is preferably effected at a temperature of about 25-30°C.


The initial salt of the base is preferably the hydrochloride in view of its ease of preparation as described in British Patent Specification 1,340,032. The maleic acid employed in this process is preferably obtained by hydrolysis of maleic anhydride in order to avoid contamination with the geometrically isomeric fumaric acid. Hydrochloric acid liberated in this process may be neutralised by the addition to the reaction mixture of an appropriate amount of a base, e.g. an alkali metal hydroxide such as sodium hydroxide, for example to adjust the pH of the reaction mixture to about 2.

With regard to process (b), this may be conveniently effected by reacting the base with maleic acid in a solvent medium, e.g., in an aqueous or more preferably an organic solvent medium, for example, comprising one or more organic solvents selected from aromatic hydrocarbons such as toluene and alkanols such as ethanol. As in process (a) above, it is preferred to obtain maleic acid by hydrolysis of maleic anhydride.

In both of processes (a) and (b) the maleic acid is advantageously employed in an approximately equimolar amount with respect to the base.

The base or salt thereof employed as starting material in processes (a) and (b) may be prepared as described in British Patent Specification 1,340,032 and, if desired, formation of the maleate salt in accordance with the present invention may be effected without isolation and/or purification of the intermediate base or salt.

A particularly preferred method described in the said British Patent Specification for the preparation of the base or a salt thereof comprises the reaction of a compound of formula (I):



(wherein Hal is chloro, bromo or iodo) with *tert*-butylamine and, if desired, converting the resulting product to an acid addition salt thereof. The above-mentioned reaction is slow in the absence of solvent since *tert*-butylamine normally reacts very slowly with 2-halopropiophenones. It is desirable to include an organic solvent in the reaction mixture, and for this purpose acetonitrile offers marked advantages. It improves the kinetics of the reaction, is unreactive under the conditions used and is relatively low boiling. Other polar solvents, protic or aprotic,

may be used, for example lower aliphatic ketones (i.e. those having from 1 to 4 carbon atoms in each alkyl group) or ethers, but the reaction is slow in these solvents. Others which may be used include dimethylformamide, dimethylacetamide, nitromethane, dimethylsulphoxide and hexamethylphosphoramide.

- 5 It may be desirable to heat the reactants, for example at the reflux temperature of the reaction mixture. The amine is preferably present in excess relative to the compound of formula (I); up to five times the equimolar quantity may be used. If Hal in formula (I) is chloro, then a catalytic amount of an iodide salt, for example sodium iodide may be included with advantage in the reaction mixture. 5
- 10 The following Examples illustrate the present invention, but should not be taken to in any way constitute a limitation thereof. 10

EXAMPLE 1

- 2-*tert*-Butylamino-3'-chloropropiophenone hydrochloride (83 g, 0.3 mole) was dissolved in 0.5 L of water and an equimolar quantity of aqueous sodium hydroxide was added. The free base of the α -aminoketone was extracted by washing with toluene (200 mL). The organic extract was diluted with an equal volume of toluene and treated dropwise with a solution of maleic acid (35 g, 0.3 mole) in ethanol (150 mL). After 30 minutes the precipitated maleate salt was removed by filtration, washed with cold toluene, and dried *in vacuo* at 50°C to give 2-*tert*-butylamino-3'-chloropropiophenone maleate as a white solid: 99.7 g (93.2%), m.p. 180–183°C; NMR(60MHz, DMSO- d_6) δ 8.3–7.6 (m, 4H, aromatic), 6.0 (s, 2H, vinyl), 5.3 (q, 1H, methine), 1.5 (d, 3H, methyl), 1.3 (s, 9H, *tert*-butyl). 15

- Anal. calcd. for $C_{17}H_{22}NO_5Cl$: C, 57.38; H, 6.23; N, 3.94; Cl 9.94.
25 Found: C, 57.47; H, 6.25; N, 3.91; Cl, 9.87. 25

EXAMPLE 2

- 2-Bromo-3'-chloropropiophenone (48 g, 0.19 mole) in acetonitrile (60 mL) was treated dropwise with *tert*-butylamine (35 g, 0.48 mole) over one hour keeping the temperature below 30°C. After an additional one hour the mixture was stripped *in vacuo* and taken up in toluene (100 mL). The insoluble *tert*-butylamine hydrobromide was removed by filtration and washed with toluene. The combined organic phases were extracted twice with excess cold aqueous hydrochloric acid and the aqueous extracts were treated with Darco G-60 for 2 hours at room temperature; then filtered and diluted to 400 mL with water. This solution was treated with an aqueous solution of maleic acid (22.6 g, 0.19 mole) with good stirring. The mixture was neutralized to pH 2 by the dropwise addition of 40% aqueous sodium hydroxide and the precipitated maleate was removed by filtration and washed with water. After slurrying with water, to remove residual ionic chloride, the cake was dried *in vacuo* at 50°C to give 2-*tert*-butylamino-3'-chloropropiophenone maleate as a white powder: 48.6 g (70.4%), m.p. 179–181°C; NMR(100 MHz, DMSO- d_6) δ 8.35–7.60 (m, 4H, aromatic), 6.05 (s, 2H, vinyl), 5.30 (q, 1H, methine), 1.45 (d, 3H, methyl), 1.30 (s, 9H, *tert*-butyl). 30

- Anal. for $C_{17}H_{22}NO_5Cl$: Calculated: C, 57.38; H, 6.23; N, 3.94; Cl, 9.94;
45 Found: C, 57.45; H, 6.26; N, 3.92; Cl, 9.94. 45

EXAMPLE 3

Tablets were prepared having the following composition:–

50 Ingredient	mg/tablet	50
Active ingredient	74.21*	
Lactose	180.79	
Starch, corn	30.00	
55 Methylcellulose	3.00	55
Magnesium stearate	3.00	
Total weight	291.00	

- 60 * equivalent to 50 mg of base. 60

A wet granulation formulation using the methylcellulose as binder was employed to make tablets of 291 mg theoretical compression weight on a single punch tablet press. The resulting tablets were 9.4 mm round, biconvex.

EXAMPLE 4

Tablets were prepared as described in Example 3 except that 12 mg of talc was substituted for the magnesium stearate, the resulting theoretical compression weight of the tablets being 300 mg.

5

5

EXAMPLE 5

Tablets were prepared having the following compositions:—

10 Ingredient	mg/tablet		10
	A	B	
Active ingredient	65*	195**	
Microcrystalline cellulose	281	151	
15 Starch, corn	30	30	15
Methylcellulose	8	8	
Talc	8	8	
Stearic acid	8	8	
20 Total weight	400	400	20

* equivalent to 44 mg of base

** equivalent to 131 mg of base

25 Method

25

The active ingredient, diluent and starch were mixed together and then granulated with an aqueous solution of methyl cellulose. After drying the granules, the talc and stearic acid were blended in and tablets compressed at an average weight of 400 mg.

30 EXAMPLE 6

30

Capsules were prepared having the following composition:—

35	Ingredient	mg/capsule	35
	Active ingredient	97.5*	
	Lactose	111.5	
	Methylcellulose 400 cps	3.0	
	Starch	24.0	
40	Talc	4.0	40
	Total fill weight	240.0	

* equivalent to 66 mg of base

45

45

The active ingredient, lactose and starch were mixed together and then granulated with a solution of the methylcellulose in water. After drying the granules, the talc was blended in and filled into hard, opaque, gelatin capsules to an average fill weight of 240 mg.

50 EXAMPLE 7

50

Capsules were prepared having the following composition:—

<hr/>		
55	Ingredient	mg/capsule
	<hr/>	
	Active ingredient	130*
	Spray Dried Lactose	99
	Sodium Starch Glycolate	7
	Talc	4
60		<hr/>
	Total fill weight	240
	<hr/>	

* equivalent to 88 mg of base

65 The active ingredient, spray dried lactose, sodium starch glycolate and talc were blended

65

together and filled into hard opaque gelatin capsules to an average fill weight of 240 mg.

EXAMPLE 8

Hard, opaque, gelatin capsules were filled with the indicated ingredients (mg/capsule):

Ingredient	Formulae			
	(A)	(B)	(C)	(D)
10 Active ingredient (equivalent to base)	64.41 (43.40)	96.61 (65.09)	128.80 (86.78)	193.20 (130.17)
Corn starch NF	48.00	39.00	52.00	62.00
Lactose, hydrous USP	343.59	194.39	259.20	325.80
Talc USP	24.00	21.00	28.00	34.00
15 Total fill weight	480.00	351.00	468.00	615.00
Capsule size	1	1	1	0

EXAMPLE 9 Comparative stability of various salts of 2-tert-butylamino-3'-chloropropiophenone

20 Small amounts of various salts of 2-tert-butylamino-3'-chloropropiophenone were each placed in a clean borosilicate glass vial which was sealed with a Teflon-faced rubber closure. The samples were then placed in an oven maintained at 70°C (except for the formate which was stored at 75°C) and visual comparisons were made over a period of 1-3 days. The observations are recorded in the following Table I:

25 **TABLE I**

Salt	Observation
30 Hydrochloride	No visible decomposition was observed over a period of 3 days.
Maleate	No visible decomposition was observed over a period of 3 days.
35 Fumarate	Extensive decomposition after 3 days as shown by severe discoloration and some fusion
Citrate	Extensive decomposition after 3 days as shown by severe discoloration and some fusion.
40 Methanesulphonate sesquihydrate	Extensive decomposition was observed over a period of several hours.
Trifluoromethanesulphonate	Extensive decomposition after 3 days as shown by severe discoloration and some fusion.
45 Phosphate monohydrate	Extensive decomposition after 3 days as shown by severe discoloration and some fusion.
Formate	Extensive decomposition after 1 day as shown by severe discoloration.

50 EXAMPLE 10

Comparative stability of tablets of Examples 3 and 4

In order to compare the storage stability of the tablets of Examples 3 and 4 similar tablets containing the hydrochloride salt of 2-tert-butylamino-3'-chloropropiophenone, tablets having the following compositions were prepared in an analogous manner to that described in Examples 3 and 4:-

Ingredient	mg/tablet		
	10A	10B	
5			5
2- <i>tert</i> -Butylamino-3'-chloropropiophenone hydrochloride	50.0	50.0	
Lactose	205.00	205.00	
Corn starch	30.00	30.00	
10 Methylcellulose (400 cps)	3.00	3.00	10
Magnesium stearate	3.00	—	
Talc	—	12.00	
Total weight	291.00	291.00	15

The four sets of tablets (3, 4, 10A and 10B) were tested for stability. Testing was carried out on tablets:

- (a) stored at 50°C in closed bottles; and
 20 (b) stored at 37°C in open bottles under a relative humidity of 75%. 20

The results are summarised in the following Table II in which the data are assay values expressed as percentage of labeled strength of the active salt, and "mo." indicates month:

TABLE II 25

Example	3	4	10A	10B
1 mo./37°C. 75% RH	97.1	99.3	*	83.3
1 mo./50°C.	97.4	100.1	18	66.4
30 3 mo./50°C.	90.0	100.5	*	*

*Samples not assayed because physical appearance of tablets showed gross signs of extreme chemical degradation.

- 35 The data given in Table II indicate that the hydrochloride salt had limited stability in the formulated tablets (Examples 10A and 10B), the instability being especially pronounced in the tablet containing magnesium stearate as lubricant. In contrast, the maleate salt was relatively stable, only comparatively slight decomposition being noted in the case when magnesium stearate was employed as lubricant. 35

40 EXAMPLE 11 40

Ingredient		mg/tablet	
45	Active ingredient	74.21*	45
	Corn Starch	37.00	
	Ethycellulose, 10 cps	12.00	
	Lactose, hydrous	500.00	
	Talc	15.00	
50	Alcohol, SD3A, anhydrous	q.s.	50
Total weight		638.21 mg	

*Equivalent to 50 mg of free base.

- 55 The active ingredient, starch and lactose were mixed together, then granulated with an alcoholic solution of ethylcellulose. After drying the granules, the talc was blended in and tablets compressed at an average weight of 638.21 mg. 55

EXAMPLE 12

Ingredient		mg/tablet	
5	Active ingredient	74.21*	5
	Microcrystalline cellulose	500.00	
	Talc	12.00	
10	Total weight	586.21 mg	10

*Equivalent to 50 mg of free base.

The active ingredient, microcrystalline cellulose and talc were mixed together. Tablets were compressed at an average weight of 586.21 mg.

EXAMPLE 13

Ingredient		mg/tablet	
20	Active ingredient	193.2*	20
	Pregelatinized Starch	387.8	
	Hydrogenated vegetable oil	12.0	
25	Total weight	593.0 mg	25

*Equivalent to 130 mg free base.

The active ingredient, pregelatinized starch and hydrogenated vegetable oil were mixed together. Tablets were compressed at an average weight of 593 mg.

EXAMPLE 14

Ingredient		mg/tablet	
35	Active ingredient	128.8*	35
	Lactose, hydrous	259.2	
	Corn Starch	52.0	
	Talc	28.0	
40	Total fill weight	468.0 mg	40

*Equivalent to 86.8 mg free base.

The active ingredient, lactose, corn starch and talc were mixed together and filled into opaque hard shell gelatin capsules to an average fill weight of 468 mg.

EXAMPLE 15

Capsules were prepared as described in Example 14 except that 10 mg stearic acid was substituted for the talc. The resulting theoretical capsule fill weight being 450 mg.

EXAMPLE 16

Capsules were prepared as described in Example 14 except that 9 mg hydrogenated vegetable oil was substituted for the talc. The resulting theoretical capsule fill weight being 449 mg.

EXAMPLE 17

5	Ingredient	mg/tablet	
	Active ingredient	193.2*	5
	Pregelatinized Starch	387.8	
	Talc	34.0	
10	Total fill weight	615.0 mg	10

*Equivalent to 130 mg free base.

The active ingredient, pregelatinized starch and talc were mixed together and filled into opaque hard shell gelatin capsules to an average fill weight of 615 mg. 15

EXAMPLE 18

20	Ingredient	mg/tablet	20
	Active ingredient	193.2*	
	Microcrystalline cellulose	313.8	
	Corn Starch	60.0	
	Talc	33.0	
25	Total fill weight	600.0 mg	25

*Equivalent to 130 mg free base.

The active ingredient, microcrystalline cellulose, corn starch, and talc were mixed together and filled into opaque hard shell gelatin capsules to an average fill weight of 600 mg. 30

EXAMPLE 19

To improve granule flow properties, a compactor may be used to dry granulate formulations cited in Examples 3 through 8. 35

EXAMPLE 20

The following capsule formulations were prepared to compare the storage stability of capsules of the maleate and hydrochloride salts of 2-*tert*-butylamino-3'-chloropropiophenone. 40

	Ingredient	A	B	C	
45	2- <i>tert</i> -butylamino-3'-chloropropiophenone maleate	130	—	—	45
	2- <i>tert</i> -butylamino-3'-chloropropiophenone hydrochloride	—	130	100.9*	
	Lactose	260	260	260	
	Corn starch	52	52	52	
50	Talc	26	26	26	50
	Total fill weight	468	468	438.9	

*Molar equivalent of 130 mg of the maleate salt

The appropriate salt was sifted through a 30 mesh screen and blended with the lactose and corn starch each of which had been sifted previously through a 60 mesh screen. Half of the talc was sifted through a 30 mesh screen and blended with the blended powders. The final blends were compacted and milled to pass through a 30 mesh screen. The remaining talc was sifted (30 mesh) over the milled powders, blended and filled into No. 1, opaque white, hard gelatin capsules. 60

Stability testing was carried out on the capsules:

(a) stored at 40°C and 50°C in closed polyethylene bottles; and

(b) stored at 40°C in open polyethylene bottles under a relative humidity of 75%.

The results are summarized in Table III in which the data are assay values expressed as 65

percentage of labeled strength of the active salt.

TABLE III

5	Storage Conditions	20 A	20 B	20 C	5
	Initial	98.6	99.7	97.9	
	3 weeks at 50°C	99.4	60.5	71.4	
	6 weeks at 50°C	99.2	49.2	66.1	
10	3 months at 40°C	98.2	84.6	82.3	10
	3 months at 50°C	96.8	41.1	64.4	
	6 weeks at 40°C/75% RH	97.9	19.3	13.2	
	3 months at 40°C/75% RH	95.0	**	**	
15	**Unfit for assay				15

EXAMPLE 21

Antitetraabenazine Activity

Antagonism of tetraabenazine induced sedation was measured using a modification of the method of Vernier, *et al.*, *First Hahnemann Symposium on Psychosomatic Medicine*, ed. Nodim and Moyer, pub. Lea and Febiger, Philadelphia, 1962.

Mice, three groups of 12 CD1 males each, were injected intraperitoneally (ip) with a solution of 2-*tert*-butylamino-3'-chloropropiophenone hydrochloride (Cpd A) or 2-*tert*-butylamino-3'-chloropropiophenone maleate (Cpd B) or with saline. Thirty minutes later each of the mice was injected ip with a solution containing 35 mg/kg tetraabenazine hydrochloride. Thirty minutes after the injection of tetraabenazine each mouse was examined for its level of exploratory behavior which was scored on a modification of the arbitrary scale defined by Vernier, *et al.* The dose of tetraabenazine used was sufficient to cause 90 to 100 percent of the mice to remain motionless even when placed in a new environment. In the test results reported 100 percent would represent total reversal of tetraabenazine effects.

Test Results

35	Compound	Dose, mg/kg (ip)	Percent Antagonism of Tetraabenazine Induced Sedation	35
	Cpd A	12.5	17.5	
		25	50	
40		50	62.5	40
	Cpd B	16.1	27.5	
		32.2	62.5	
		64.4	60	
45	Saline	0	10	45

The doses of Cpd B are equivalent to the corresponding doses of Cpd A on a molar basis.

EXAMPLE 22

Toxicity Data

2-*Tert*-butylamino-3'-chloropropiophenone maleate was administered by gavage in 0.5 percent carboxymethylcellulose to Charles River CD1 mice (four males and four females) at a dose of 260 mg/kg per day for 14 days. All of the mice survived this regimen.

In EXAMPLES 3-8 and 11-19 above "Active ingredient" is 2-*tert*-butylamino-3'-chloropropiophenone maleate.

CLAIMS

1. 2-*tert*-Butylamino-3'-chloropropiophenone maleate.
2. 2-*tert*-Butylamino-3'-chloropropiophenone maleate (1:1).
3. A compound according to either of claims 1 and 2, for use in human or veterinary medicine.
4. A compound according to either of claims 1 and 2, for use in the treatment of depression in man.
5. A compound according to either of claims 1 and 2, for use in the treatment in man of a

- condition selected from:
- minimal brain dysfunction
 - tardive dyskinesia
 - mania
- 5 -hypercholesterolaemia 5
- hyperprolactinaemia and other conditions wherein reduced prolactin secretion is desirable
 - mental functional impairment caused by ethanol consumption, and
 - functional impairment and drowsiness caused by the use of benzodiazepines.
6. A pharmaceutical composition comprising 2-*tert*-butylamino-3'-chloropropiophenone maleate together with an acceptable carrier therefor. 10
7. A pharmaceutical composition comprising 2-*tert*-butylamino-3'-chloropropiophenone maleate (1:1) together with an acceptable carrier therefor.
8. A composition according to either of claims 6 and 7, suitable for oral administration.
9. A composition according to either of claims 6 and 7, suitable for parenteral administration. 15
10. A composition according to either of claims 6 and 7, suitable for rectal administration.
11. A composition according to either of claims 6 and 7 comprising the maleate in solution in an aqueous medium.
12. A composition according to any of claims 6 to 11 in unit dosage form containing a non-toxic amount of the maleate. 20
13. A composition according to claim 12 in the form of a tablet suitable for oral administration.
14. A composition according to claim 12 in the form of a capsule suitable for oral administration.
- 25 15. A composition according to claim 12 in the form of a sterile injection solution suitable for parenteral administration. 25
16. A composition according to claim 12 in the form of a suppository suitable for rectal administration.
17. A unit dosage composition according to claim 12, suitable for oral or rectal administration, containing from 15 mg. to 500 mg. (calculated as the base) of the maleate. 30
18. A unit dosage composition according to claim 17 containing from 40 mg. to 150 mg. (calculated as the base) of the maleate.
19. A unit dosage composition according to claim 12, suitable for parenteral administration, containing from 7.5 mg. to 250 mg. (calculated as the base) of the maleate.
- 35 20. A unit dosage composition according to claim 19 containing from 20 mg. to 75 mg. (calculated as the base) of the maleate. 35
21. A method for the preparation of a composition according to any of claims 6 to 20 comprising admixture of the ingredients thereof.
22. A method for the preparation of 2-*tert*-butylamino-3'-chloropropiophenone maleate according to either of claims 1 and 2, comprising reacting 2-*tert*-butylamino-3'-chloropropiophenone or another salt thereof with maleic acid or a functional equivalent thereof. 40
23. A method according to claim 22 wherein the said other salt of 2-*tert*-butylamino-3'-chloropropiophenone is the hydrochloride.
24. A method according to either of claims 22 and 23 wherein the propiophenone or salt thereof is reacted with maleic acid. 45
25. 2-*tert*-Butylamino-3'-chloropropiophenone maleate according to either of claims 1 and 2, when prepared by a method according to any of claims 22 to 24.
26. 2-*tert*-Butylamino-3'-chloropropiophenone maleate, substantially as hereinbefore described with particular reference to the accompanying Examples.
- 50 27. A pharmaceutical composition, substantially as hereinbefore described with particular reference to the accompanying Examples, comprising 2-*tert*-butylamino-3'-chloropropiophenone maleate as active ingredient. 50
28. A method substantially as hereinbefore described, with particular reference to the accompanying Examples, for the preparation of 2-*tert*-butylamino-3'-chloropropiophenone maleate. 55
29. A method for the treatment of depression in a human being which comprises administering to said human being a non-toxic, effective antidepressant amount of 2-*tert*-butylamino-3'-chloropropiophenone maleate according to either of claims 1 and 2.
30. A method for the treatment in a human being of a condition selected from:
- minimal brain dysfunction
 - tardive dyskinesia
 - mania
 - hypercholesterolaemia
 - hyperprolactinaemia and other conditions wherein reduced prolactin secretion is desirable
 - mental functional impairment caused by ethanol consumption, and
- 60 60
- 65 65

-functional impairment and drowsiness caused by the use of benzodiazepines
which comprises administering to said human being a non-toxic, treatment-effective amount of
2-*tert*-butylamino-3'-chloropropiophenone maleate according to either of claims 1 and 2.

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.—1984.

Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.